Apellis Pharmaceuticals released 24-month data from the phase 3 OAKS and DERBY trials of its investigational treatment for geographic atrophy (GA).
The results from the trials showed that both monthly and every-other-month intravitreal injections of pegcetacoplan demonstrated a clinically meaningful reduction in GA lesion growth from baseline compared to sham.
Looking for a rundown on this drug? Read it here. (via)
Meanwhile, Iveric Bio is also working on a treatment for GA. The company recently announced positive topline results from GATHER2, its second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor.
GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. (via)